ProfileGDS5678 / 1417547_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 68% 67% 70% 69% 68% 68% 68% 65% 67% 67% 68% 69% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1675868
GSM967853U87-EV human glioblastoma xenograft - Control 24.1706268
GSM967854U87-EV human glioblastoma xenograft - Control 34.0445167
GSM967855U87-EV human glioblastoma xenograft - Control 44.4923270
GSM967856U87-EV human glioblastoma xenograft - Control 54.2529969
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1788268
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1617968
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1525968
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9198165
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.10167
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1023267
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1890768
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2144569
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3521170